Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Engrail Therapeutics has successfully closed an oversubscribed $157 million Series B financing round, attracting attention and congratulations from various venture capital entities and industry observers. The funding, aimed at advancing the development of transformational therapies for neuropsychiatric and neurodevelopmental disorders, was led by notable figures including Vikram Sudarsan (@hypoxicfly). Venture capital firms such as FPrime Capital and Ysios Capital have publicly acknowledged their participation and support for Engrail's mission. Additionally, the venture capital and biotech sectors are witnessing significant personnel movements, with Elaine Stead joining MSeqVC's investment team and Gabriella joining Felicis as a deal partner. These developments underscore the vibrant investment interest and dynamism within the biotech and deep tech sectors.
So excited to share that @reallygabriella is joining our investment team @felicis ! Gaby has degrees in Mechanical Engineering and Computer Science from @MIT and previously worked as a PM at Google, a product engineer at Apple, and a software engineer at Meta. We’re incredibly…
We're thrilled to announce @reallygabriella is joining the Felicis investment team! Gaby worked on AR & infrastructure at Google, mechanical systems at Apple and as an engineer at Meta. She studied Mechanical Engineering and Computer Science at MIT. https://t.co/hzdSb9S6hq https://t.co/PXsyWW7rIb
excited to join @felicis as a deal partner and work with a team I've long admired including @asenkut, @speechu, @vivfaga, @victoriatr, @nikipez and @AstasiaMyers i'll be investing in my favorite areas of deeptech, applied ML, and infrastructure from inception through Series A
